EA201391351A1 - Способы повышения эффективности folr1 терапии рака - Google Patents
Способы повышения эффективности folr1 терапии ракаInfo
- Publication number
- EA201391351A1 EA201391351A1 EA201391351A EA201391351A EA201391351A1 EA 201391351 A1 EA201391351 A1 EA 201391351A1 EA 201391351 A EA201391351 A EA 201391351A EA 201391351 A EA201391351 A EA 201391351A EA 201391351 A1 EA201391351 A1 EA 201391351A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- increasing
- efficiency
- cancer therapy
- folr1
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 title abstract 2
- 102100035139 Folate receptor alpha Human genes 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 102000053180 human FOLR1 Human genes 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Предоставляются способы повышения возможности успеха при таргетной терапии рака, направленной против человеческого рецептора фолата 1. Наборы включают реагенты для использования с помощью дополнительно предусмотренных способов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471007P | 2011-04-01 | 2011-04-01 | |
PCT/US2012/031544 WO2012135675A2 (en) | 2011-04-01 | 2012-03-30 | Methods for increasing efficacy of folr1 cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201391351A1 true EA201391351A1 (ru) | 2014-11-28 |
EA028805B1 EA028805B1 (ru) | 2018-01-31 |
Family
ID=46932392
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391351A EA028805B1 (ru) | 2011-04-01 | 2012-03-30 | Способы повышения эффективности folr1 терапии рака |
EA201791843A EA201791843A3 (ru) | 2011-04-01 | 2012-03-30 | Способы повышения эффективности folr1 терапии рака |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791843A EA201791843A3 (ru) | 2011-04-01 | 2012-03-30 | Способы повышения эффективности folr1 терапии рака |
Country Status (29)
Country | Link |
---|---|
US (4) | US8709432B2 (ru) |
EP (4) | EP3636279B1 (ru) |
JP (6) | JP6018621B2 (ru) |
KR (6) | KR102101160B1 (ru) |
CN (3) | CN114441757A (ru) |
AU (4) | AU2012236219B2 (ru) |
BR (1) | BR112013025415B1 (ru) |
CA (2) | CA3182262A1 (ru) |
CY (1) | CY1119960T1 (ru) |
DK (1) | DK2694106T3 (ru) |
EA (2) | EA028805B1 (ru) |
ES (2) | ES2661466T3 (ru) |
HK (1) | HK1254759A1 (ru) |
HR (1) | HRP20180358T1 (ru) |
HU (1) | HUE036172T2 (ru) |
IL (5) | IL303208A (ru) |
LT (1) | LT2694106T (ru) |
ME (1) | ME03025B (ru) |
MX (3) | MX340640B (ru) |
MY (2) | MY180894A (ru) |
NO (1) | NO2893540T3 (ru) |
PL (1) | PL2694106T3 (ru) |
PT (1) | PT2694106T (ru) |
RS (1) | RS56916B1 (ru) |
SG (2) | SG193514A1 (ru) |
SI (1) | SI2694106T1 (ru) |
TR (1) | TR201802659T4 (ru) |
UA (2) | UA125636C2 (ru) |
WO (1) | WO2012135675A2 (ru) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
ES2390826T3 (es) | 2005-08-24 | 2012-11-16 | Immunogen Inc | Procedimiento para preparar conjugados de fármaco purificados |
HUE043645T2 (hu) | 2009-06-03 | 2019-08-28 | Immunogen Inc | Konjugációs módszerek |
DK2538976T3 (en) | 2010-02-24 | 2017-02-27 | Immunogen Inc | IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF |
PL2691155T3 (pl) | 2011-03-29 | 2019-06-28 | Immunogen, Inc. | Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem |
EA028805B1 (ru) | 2011-04-01 | 2018-01-31 | Иммьюноджен, Инк. | Способы повышения эффективности folr1 терапии рака |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
US10035817B2 (en) | 2012-10-04 | 2018-07-31 | Immunogen, Inc. | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
WO2014087863A1 (ja) * | 2012-12-07 | 2014-06-12 | 協和発酵キリン株式会社 | 抗folr1抗体 |
WO2014100762A1 (en) | 2012-12-21 | 2014-06-26 | Biolliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
RU2015149285A (ru) * | 2013-05-14 | 2017-06-19 | Иммьюноджен Инк. | Схемы дозирования иммуноконъюгата anti-folr1 |
AU2014312086B2 (en) * | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
KR20220136468A (ko) * | 2013-10-08 | 2022-10-07 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투여 레지멘 |
WO2015149018A1 (en) * | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
JP2017528418A (ja) * | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
US9669102B2 (en) | 2014-09-03 | 2017-06-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
SI3221355T1 (sl) | 2014-11-20 | 2021-01-29 | F. Hoffmann-La Roche Ag | Kombinirano zdravljenje z bispecifičnimi molekulami CD3, ki aktivirajo celice T in vežejo antigene in folatni receptor 1 (FoIR1) ter antagonisti za vezavo osi PD-1 |
US9746477B2 (en) * | 2015-07-30 | 2017-08-29 | Expression Pathology, Inc. | Quantifying FR-α and GART proteins for optimal cancer therapy |
CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
EP4353319A2 (en) | 2016-09-28 | 2024-04-17 | Atossa Therapeutics, Inc. | Methods of adoptive cell therapy |
CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
IT201700087291A1 (it) * | 2017-07-28 | 2019-01-28 | Fondazione St Italiano Tecnologia | Metodo di imaging di un campione biologico e relativa sonda |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
WO2019177854A1 (en) * | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
CN113631194A (zh) | 2019-03-21 | 2021-11-09 | 伊缪诺金公司 | 制备细胞结合剂-药物缀合物的方法 |
CN113661172A (zh) | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
PT3958977T (pt) | 2019-04-26 | 2023-12-15 | Immunogen Inc | Derivados de camptotecina |
TW202100557A (zh) | 2019-04-29 | 2021-01-01 | 美商免疫遺傳股份有限公司 | 雙互補位FR-α抗體及免疫結合物 |
JP2022534808A (ja) * | 2019-06-06 | 2022-08-03 | ミシック セラピューティクス インコーポレイテッド | 抗原結合タンパク質構築物およびその使用 |
CN111579798A (zh) * | 2020-05-29 | 2020-08-25 | 深圳市锦欣医疗科技创新中心有限公司 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
TW202306995A (zh) * | 2021-06-04 | 2023-02-16 | 美商免疫遺傳股份有限公司 | 治療具有可溶性FR-α之患者之癌症 |
WO2023170216A1 (en) * | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
CN117741149A (zh) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Univ Texas | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
HUP0300421A2 (hu) | 2000-03-31 | 2003-06-28 | Purdue Research Foundation | Kezelési eljárás ligand-immunogén konjugátumok felhasználásával |
DE10037759A1 (de) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
PL362414A1 (en) | 2001-02-19 | 2004-11-02 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
PL367102A1 (en) | 2001-05-02 | 2005-02-21 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
AU2003211337A1 (en) | 2002-03-01 | 2003-09-16 | Japan Envirochemicals, Ltd. | Proteins capable of binding to female sex hormones and process for producing the same |
CA2482607C (en) | 2002-04-22 | 2013-06-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
AU2003295411A1 (en) | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
NZ543960A (en) | 2003-05-09 | 2008-11-28 | Univ Duke | CD20-specific antibodies and methods of employing same |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2004110498A2 (en) | 2003-05-14 | 2004-12-23 | Immunogen, Inc. | Drug conjugate composition |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
AU2004253953A1 (en) | 2003-07-02 | 2005-01-13 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2548942C (en) | 2003-12-05 | 2013-10-15 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
JP4805848B2 (ja) * | 2004-02-12 | 2011-11-02 | モルフォテック、インク. | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
EP2214018B1 (en) | 2004-04-27 | 2013-06-26 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2007044043A2 (en) | 2004-12-21 | 2007-04-19 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
EA200701211A1 (ru) | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
CN101203759A (zh) * | 2005-03-30 | 2008-06-18 | 普渡研究基金会 | 使用细胞叶酸维生素受体定量法而用于癌症预后的方法 |
EP1879922A2 (en) | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EP1888639A1 (en) | 2005-05-12 | 2008-02-20 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-dsc2 antibody |
JP4991705B2 (ja) | 2005-05-20 | 2012-08-01 | ロンザ・バイオロジクス・ピーエルシー | 哺乳類宿主細胞における組換え抗体の高レベル発現 |
BRPI0610203A2 (pt) | 2005-05-24 | 2010-06-01 | Avestha Gengraine Tech Pvt Ltd | processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica |
EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
CA2619725C (en) | 2005-08-18 | 2016-06-07 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
CA2621363C (en) | 2005-09-13 | 2015-07-07 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
AU2006304605A1 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
CA2994756C (en) | 2005-12-20 | 2020-10-27 | Sbi Biotech Co., Ltd. | Anti-ilt7 antibody |
WO2007143561A1 (en) | 2006-06-01 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
EP2032701B1 (en) | 2006-06-23 | 2013-11-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptides involved in cancer |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
EP1900533A1 (de) | 2006-09-16 | 2008-03-19 | J. Zimmer Maschinenbau Gesellschaft m.b.H. | Vorrichtung zum Auftragen von Substanz auf flächige Substrate |
CN101594883B (zh) | 2006-10-12 | 2018-04-10 | 中外制药株式会社 | 使用抗ereg抗体的癌症的诊断和治疗 |
EP2103628A4 (en) | 2006-12-14 | 2012-02-22 | Forerunner Pharma Res Co Ltd | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY |
AU2007338607B2 (en) | 2006-12-20 | 2013-03-14 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
EP2609934A1 (en) | 2007-02-16 | 2013-07-03 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
AU2008282863A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
CN101139613B (zh) | 2007-08-01 | 2011-06-08 | 姜荣锡 | 抗肿瘤二元多肽及其应用与制备方法 |
US20090087849A1 (en) * | 2007-09-06 | 2009-04-02 | Tripath Imaging, Inc. | Nucleic acid-based methods and compositions for the detection of ovarian cancer |
EP2227549B1 (en) | 2007-12-21 | 2015-06-17 | Novartis AG | Selection system for eukaryotic cell culture based on a membrane-bound folate receptor gene |
CA2711557A1 (en) | 2008-01-11 | 2009-07-16 | The University Of Tokyo | Anti-cldn6 antibody |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
AU2009243010B2 (en) | 2008-04-30 | 2015-02-05 | Immunogen, Inc. | Cross-linkers and their uses |
US8383351B2 (en) | 2008-06-11 | 2013-02-26 | Oxford Brookes University | Antibody to inhibin/ activin β-B subunit |
EP2349274A4 (en) | 2008-09-17 | 2014-12-17 | Endocyte Inc | CONJUGATES OF ANTIFOLATES BINDING THE FOLATE RECEPTOR |
WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
US8420329B2 (en) | 2008-11-20 | 2013-04-16 | Oncotherapy Science, Inc. | Methods for diagnosing or treating prostate cancer |
CN101440130B (zh) | 2008-11-21 | 2011-07-27 | 中国人民解放军第四军医大学 | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 |
WO2010111388A2 (en) | 2009-03-24 | 2010-09-30 | Biocept, Inc. | Devices and methods of cell capture and analysis |
WO2011016238A1 (en) * | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011032296A1 (en) | 2009-09-21 | 2011-03-24 | Mount Sinai Hospital | Methods and compositions for the diagnosis and treatment of thyroid cancer |
AR080155A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos anti-cd20 y su utilizacion |
DK2538976T3 (en) * | 2010-02-24 | 2017-02-27 | Immunogen Inc | IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF |
ES2627061T3 (es) * | 2010-11-05 | 2017-07-26 | Morphotek, Inc. | Folato receptor alfa como diagnóstico y pronóstico para el folato marcador receptor de los cánceres expresores de alfa |
KR20140019415A (ko) * | 2011-03-29 | 2014-02-14 | 이뮤노젠 아이엔씨 | 향상된 균질성의 접합체를 제조하기 위한 방법 |
WO2012135517A2 (en) * | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
PL2691155T3 (pl) * | 2011-03-29 | 2019-06-28 | Immunogen, Inc. | Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem |
EA028805B1 (ru) * | 2011-04-01 | 2018-01-31 | Иммьюноджен, Инк. | Способы повышения эффективности folr1 терапии рака |
US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
US9156854B2 (en) | 2011-04-18 | 2015-10-13 | Immunogen, Inc. | Maytansinoid derivatives with sulfoxide linker |
PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
WO2014055842A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
RU2015149285A (ru) | 2013-05-14 | 2017-06-19 | Иммьюноджен Инк. | Схемы дозирования иммуноконъюгата anti-folr1 |
AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
KR20220136468A (ko) * | 2013-10-08 | 2022-10-07 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투여 레지멘 |
WO2015149018A1 (en) * | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
WO2016004233A2 (en) | 2014-07-01 | 2016-01-07 | Expression Pathology, Inc. | Srm assays to chemotherapy targets |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
BR112019023909A8 (pt) | 2017-05-16 | 2023-04-11 | Immunogen Inc | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab |
-
2012
- 2012-03-30 EA EA201391351A patent/EA028805B1/ru unknown
- 2012-03-30 KR KR1020197014502A patent/KR102101160B1/ko active IP Right Grant
- 2012-03-30 UA UAA201609144A patent/UA125636C2/uk unknown
- 2012-03-30 CA CA3182262A patent/CA3182262A1/en active Pending
- 2012-03-30 PL PL12764885T patent/PL2694106T3/pl unknown
- 2012-03-30 ES ES12764885.5T patent/ES2661466T3/es active Active
- 2012-03-30 IL IL303208A patent/IL303208A/en unknown
- 2012-03-30 AU AU2012236219A patent/AU2012236219B2/en active Active
- 2012-03-30 KR KR1020207010226A patent/KR20200039843A/ko active Application Filing
- 2012-03-30 ME MEP-2018-59A patent/ME03025B/me unknown
- 2012-03-30 UA UAA201312203A patent/UA113403C2/uk unknown
- 2012-03-30 WO PCT/US2012/031544 patent/WO2012135675A2/en active Application Filing
- 2012-03-30 CN CN202111663548.0A patent/CN114441757A/zh active Pending
- 2012-03-30 HU HUE12764885A patent/HUE036172T2/hu unknown
- 2012-03-30 KR KR1020217021056A patent/KR102489185B1/ko active IP Right Grant
- 2012-03-30 EP EP19192583.3A patent/EP3636279B1/en active Active
- 2012-03-30 BR BR112013025415-7A patent/BR112013025415B1/pt active IP Right Grant
- 2012-03-30 MX MX2013011098A patent/MX340640B/es active IP Right Grant
- 2012-03-30 DK DK12764885.5T patent/DK2694106T3/en active
- 2012-03-30 JP JP2014502848A patent/JP6018621B2/ja active Active
- 2012-03-30 EP EP12764885.5A patent/EP2694106B1/en active Active
- 2012-03-30 LT LTEP12764885.5T patent/LT2694106T/lt unknown
- 2012-03-30 IL IL281714A patent/IL281714B2/en unknown
- 2012-03-30 KR KR1020247002873A patent/KR20240017965A/ko not_active Application Discontinuation
- 2012-03-30 EP EP17206669.8A patent/EP3318273B1/en active Active
- 2012-03-30 RS RS20180231A patent/RS56916B1/sr unknown
- 2012-03-30 SG SG2013070040A patent/SG193514A1/en unknown
- 2012-03-30 CA CA2831426A patent/CA2831426C/en active Active
- 2012-03-30 CN CN201280015187.1A patent/CN103747802B/zh active Active
- 2012-03-30 MY MYPI2013003422A patent/MY180894A/en unknown
- 2012-03-30 US US13/435,857 patent/US8709432B2/en active Active
- 2012-03-30 KR KR1020137028854A patent/KR101982317B1/ko active IP Right Grant
- 2012-03-30 PT PT127648855T patent/PT2694106T/pt unknown
- 2012-03-30 EP EP23196667.2A patent/EP4309671A3/en active Pending
- 2012-03-30 MX MX2015009802A patent/MX346555B/es unknown
- 2012-03-30 EA EA201791843A patent/EA201791843A3/ru unknown
- 2012-03-30 SG SG10201602553VA patent/SG10201602553VA/en unknown
- 2012-03-30 ES ES19192583T patent/ES2965109T3/es active Active
- 2012-03-30 MY MYPI2017001279A patent/MY186591A/en unknown
- 2012-03-30 TR TR2018/02659T patent/TR201802659T4/tr unknown
- 2012-03-30 SI SI201231241T patent/SI2694106T1/en unknown
- 2012-03-30 KR KR1020237001305A patent/KR20230013283A/ko not_active Application Discontinuation
- 2012-03-30 CN CN201810367278.0A patent/CN108743965A/zh active Pending
- 2012-10-26 NO NO12884208A patent/NO2893540T3/no unknown
-
2013
- 2013-09-26 MX MX2019010336A patent/MX2019010336A/es unknown
- 2013-09-29 IL IL228538A patent/IL228538B/en active IP Right Grant
-
2014
- 2014-04-04 US US14/245,797 patent/US20140363453A1/en not_active Abandoned
-
2016
- 2016-05-09 JP JP2016093915A patent/JP2016147901A/ja active Pending
-
2017
- 2017-05-02 AU AU2017202927A patent/AU2017202927B2/en active Active
- 2017-11-09 US US15/807,831 patent/US11135305B2/en active Active
-
2018
- 2018-02-27 CY CY20181100241T patent/CY1119960T1/el unknown
- 2018-02-27 HR HRP20180358TT patent/HRP20180358T1/hr unknown
- 2018-04-03 JP JP2018071500A patent/JP2018118997A/ja active Pending
- 2018-10-29 HK HK18113802.1A patent/HK1254759A1/zh unknown
- 2018-11-12 IL IL262956A patent/IL262956B/en active IP Right Grant
-
2019
- 2019-04-15 AU AU2019202611A patent/AU2019202611B2/en active Active
- 2019-08-06 JP JP2019144277A patent/JP2019194257A/ja active Pending
-
2020
- 2020-03-25 IL IL273614A patent/IL273614A/en unknown
- 2020-09-29 JP JP2020163354A patent/JP2021006547A/ja active Pending
-
2021
- 2021-07-21 AU AU2021206842A patent/AU2021206842A1/en active Pending
- 2021-08-31 US US17/463,156 patent/US20220143208A1/en active Pending
-
2022
- 2022-02-10 JP JP2022019315A patent/JP2022062219A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
CY1124024T1 (el) | Νεες ctla4-ig ανοσοπροσκολλητινες | |
ZA201907607B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
CY2019008I1 (el) | Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
MX2021003858A (es) | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. | |
EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
TWD161529S (zh) | 治療燈 | |
EA032986B1 (ru) | Пирролобензодиазепины | |
CR20110553A (es) | Terapia complementaria contra el cáncer | |
MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
EA201590650A1 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
IN2015MN00001A (ru) | ||
MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
CY1121275T1 (el) | Θεραπεια των διαταραχων του εθισμου και του ελεγχου της παρορμητικοτητας χρησιμοποιωντας αναστολεις pde7 |